INTRODUCTION: Atrial fibrillation is a supraventricular tachyarrhythmia, which is characterised by the presence of fast and uncoordinated atrial activation leading to reduced atrial mechanical function. Risk factors for atrial fibrillation include increasing age, coexisting cardiac and thyroid disease, pyrexial illness, electrolyte imbalance, cancer, and coexisting infection. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of oral medical treatments to control heart rate in people with chronic (defined as longer than 1 week for this review) non-valvular atrial fibrillation? What is the effect of different treatment strategies (rate vs. rhythm) for people with persistent non-valvular atrial fibrillation? We searched: Medline, Embase, The Cochrane Library and other important databases up to August 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 18 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: beta-blockers (with or without digoxin), calcium channel blockers (with or without digoxin), calcium channel blockers (rate limiting), digoxin, and rate versus rhythm control strategies.
INTRODUCTION:Atrial fibrillation is a supraventricular tachyarrhythmia, which is characterised by the presence of fast and uncoordinated atrial activation leading to reduced atrial mechanical function. Risk factors for atrial fibrillation include increasing age, coexisting cardiac and thyroid disease, pyrexial illness, electrolyte imbalance, cancer, and coexisting infection. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of oral medical treatments to control heart rate in people with chronic (defined as longer than 1 week for this review) non-valvular atrial fibrillation? What is the effect of different treatment strategies (rate vs. rhythm) for people with persistent non-valvular atrial fibrillation? We searched: Medline, Embase, The Cochrane Library and other important databases up to August 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 18 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: beta-blockers (with or without digoxin), calcium channel blockers (with or without digoxin), calcium channel blockers (rate limiting), digoxin, and rate versus rhythm control strategies.
Authors: D L Murdoch; K O'Neill; J Jackson; A McMahon; A Rumley; I Wallace; G D O Lowe; R C Tait Journal: Scott Med J Date: 2005-11 Impact factor: 0.729
Authors: F D R Hobbs; D A Fitzmaurice; J Mant; E Murray; S Jowett; S Bryan; J Raftery; M Davies; G Lip Journal: Health Technol Assess Date: 2005-10 Impact factor: 4.014
Authors: Cyrus R Kumana; Bernard M Y Cheung; Giselle T Y Cheung; Tori Ovedal; Bjorn Pederson; Ian J Lauder Journal: Br J Clin Pharmacol Date: 2005-10 Impact factor: 4.335
Authors: K K Koh; J H Song; K S Kwon; H B Park; S H Baik; Y S Park; H H In; T H Moon; G S Park; S K Cho Journal: Int J Cardiol Date: 1995-11-24 Impact factor: 4.164
Authors: Mina K Chung; Lynn Shemanski; David G Sherman; H Leon Greene; David B Hogan; Joyce C Kellen; Soo G Kim; Lisa Warsinger Martin; Yves Rosenberg; D George Wyse Journal: J Am Coll Cardiol Date: 2005-10-21 Impact factor: 24.094
Authors: Luca Testa; Giuseppe G L Biondi-Zoccai; Antonio Dello Russo; Fulvio Bellocci; Felicita Andreotti; Filippo Crea Journal: Eur Heart J Date: 2005-05-04 Impact factor: 29.983